Key result
Induction therapy for ≥6 months linked to ~67% lower lupus nephritis flare risk after remission.
Why the study?
Despite standard treatment guidelines for lupus nephritis, a substantial proportion of patients experience flares after achieving complete remission.
What is the incidence of and factors associated with lupus nephritis flares after complete response in a Thai population?
Cohort (n=87)
No
What is the incidence of and factors associated with lupus nephritis flares after complete response in a Thai population?
Hazard Ratio: 0.33 (95% CI 0.15–0.73)
p-value: p=0.006
Almost half of lupus nephritis patients experience a flare within a few years after achieving complete remission, though longer induction therapy and statin use may reduce this risk.
Substantial post-remission flare rates in lupus nephritis warrant close monitoring; extends induction-duration observations yet leaves practice change hypothesis-generating.
Background: Nowadays, we have standard treatment guidelines for lupus nephritis (LN), a substantial proportion of patients have LN flare. The aims here to determine the incidence of LN flare in patients who had renal complete remission (CR) after receiving induction therapy (IT) and to identify factors associated with renal flare after CR in clinical practice. Methods: Retrospective analysis in a tertiary-level center for the clinical outcomes of patients who had first LN episode, achieved CR (24hr urine protein <0.5 gm/day with normal renal function) within 12 months after received IT and received the maintenance therapy (MT). Results: Eighty-seven out of 548 patients (96.6% female with mean age 29.5±10.8 years) met the inclusion criteria. During 6.1±3.4 years of observation after CR, 42 (48.3%) patients had LN flare. The incidence ratio of LN flare was 10.9/100 patient-years. The mean time from CR to flare was 3.1 years. Using Cox-regression analysis, induction to remission therapy ≥6 months (OR=0.33, p=0.006), and using statins ≥9 months after reached CR (OR=0.44, p=0.032) had a lower incidence of LN flare, while age at onset of disease ≤20 years had a higher incidence of LN flare. Conclusion: Despite achieving CR with standard treatment, almost half of the patients had an LN flare within a few years. Young SLE patients had an increased incidence of LN flare, the long period of induction therapy and using statins may retard a flare of the disease.
No takes yet. Share an insight, caveat, or question.
Sankhaanuruk et al. (2022) conducted a cohort in Lupus Nephritis (n=87). Induction therapy ≥6 months vs. Induction therapy <6 months was evaluated on Lupus nephritis flare (HR 0.33, 95% CI 0.15-0.73, p=0.006). Despite achieving complete remission, 48.3% of lupus nephritis patients experienced a flare, though induction therapy for ≥6 months significantly reduced this risk (HR 0.33).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: